Drug repositioning: bringing new life to shelved assets and existing drugs

With Viagra the most famous example, drug repositioning has been growing in importance for pharmaceutical companies seeking to reinvigorate development pipelines. This book provides a broad overview of drug repositioning including the business reasons and unique opportunities and challenges. Its coverage also presents a number of current and emerging technologies that are being applied,along with relevant case studies, as well as neglected diseases to consider. Pharmaceutical researchers will learn how to use drug repositioning techniquesto increase the lifespan and applications of their drugs, and also decrease both costs and development time. INDICE: IntroductionMichael Barratt and Donald FrailPart 1. Drug Repositioning: Business Case, Strategies and Operational Considerations1. Drug Repositioning: The Business Case and Current Strategies to Repurpose Shelved Candidates and Marketed DrugsJohn Arrowsmith and Richard Harrison2. Opportunities and challenges associated with developing additional indications for clinical development candidates and marketed drugsDonald Frail and Michael Barratt3. Clinical and operational considerations in repositioning marketed drugs and drug candidatesDamian O’Connell, David Sequeira and Maria Miller4. Regulatory considerations and strategies for drug repositioningKen PhelpsPart 2. Application of Technology Platforms to Uncover New Indications and Repurpose Existing Drugs5. Computational and Bioinformatic Strategies for Drug RepositioningRichard Mazzarella and Craig Webb6. Mining scientific and clinical databases to identify novel uses for existing drugsChristos Andronis, Anuj Sharma, Spyros Deftereos, Vassilis Virvilis, Ourania Konstanti, Andreas Persidis and Aris Persidis7. Predicting the polypharmacology of drugs: Identifying new uses through chemoinformatics, structural informatics and molecular modeling based approachesLi Xie, Sarah Kinnings, Lei Xie and Philip Bourne8. Systemic phenotypic screening for novel synergistic combinations: A new paradigm for repositioning existing drugsMargaret Lee9. Phenotypic in vivo screening to identify new, unpredicted indications for existing drugs and drug candidatesMichael Saporito, Christopher Lipinski and Andrew Reaume10. Old Drugs Yield New Discoveries: Examples from the Prodrug, Chiral Switch and Site-Selective Deuteration StrategiesAdam Morgan, Bhaumik Pandya, Craig Masse and Scott HarbesonPart 3. Academic and Non-Profit Initiatives & the Role of Alliances in the Drug Repositioning Industry11. Repurposing Drugs for Tropical Diseases: Case Studies and Open-source Screening InitiativesCurtis Chong12. Drug Repositioning Efforts by Non-Profit Foundations12.1 Repositioning Drugs for Leukemia and Lymphoma: Perspective From The Leukemia & Lymphoma SocietyLouis DeGennaro, Aaron Schimmer, James Kasper and Richard Winneker12.2 Repositioning drugs for Parkinson’s disease: Perspective from the Michael J. Fox FoundationTodd Sherer, Alison Urkowitz, and Kuldip Dave12.3 Repositioning drugs for Polycystic Kidney Disease (PKD): Perspectives from the Polycystic Kidney Disease FoundationJill Panetta and John McCall13. Business Development Strategies in the Repositioning IndustryAris Persidis and Elizabeth Stark14. A Case Study in Drug Repositioning: SoseiAkinori Mochizuki andMakiko Aoyama

• ISBN: 978-0-470-87827-9
• Editorial: John Wiley & Sons
• Encuadernacion: Cartoné
• Páginas: 498
• Fecha Publicación: 01/06/2012
• Nº Volúmenes: 1
• Idioma: Inglés